<DOC>
	<DOCNO>NCT02440230</DOCNO>
	<brief_summary>To compare safety adjuvant OFS combine anastrozole versus OFS combine exemestane Chinese premenopausal hormonal receptor ( HR ) positive breast cancer patient .</brief_summary>
	<brief_title>Safety OFS Combined With AI Endocrine Therapy Chinese Premenopausal Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>1 . Women age ≥18 year ; 2 . Histologically confirm invasive breast cancer core needle biopsy surgery , hormonal receptor positive , define estrogen receptor ( ER ) /progesterone receptor ( PR ) positive ; 3 . Premenopausal define menstruate regularly 6 month prior randomization use form hormonal contraception hormonal treatment 6 month prior randomization . premenopausal status confirm estradiol ( E2 ) premenopausal range chemotherapy related amenorrhea ; 4 . Patients must receive standard local therapy : normalize modify radical mastectomy breast conserve surgery negative margin postsurgical radiotherapy . Patient complete adjuvant therapy accord condition , include adjuvant radiotherapy , neoadjuvant adjuvant chemotherapy ; 5 . Patients receive chemotherapy randomize within 24 week definitive surgery.Patients receive prior adjuvant and/or neoadjuvant chemotherapy randomize complete chemotherapy within 8 month final dose chemotherapy soon premenopausal status confirm ; 6 . Leukocyte ≥ 3*109/L ; Platelets ≥ 75*109/L ; Serum glutamate ; 7. oxaloacetate ( AST/SGOT ) serum glutamicpyruvic transaminase ( ALT/SGPT ) &lt; 2.5 time upper limit normal ( UNL ) range ; 8 . Serum creatinine/blood urea nitrogen ( BUN ) ≤ upper limit normal ( UNL ) range ; 9 . Written inform consent accord local ethic committee requirement . 10 . Has Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 ; 1 . Histologically confirm hormonal receptor negative . 2 . Postmenopausal . 3 . Patients inoperable local advance breast cancer include inflammatory breast cancer supraclavicular node involvement enlarge internal mammary node ( unless pathologically negative ) . 4 . Definitive surgery do 24 week randomization patient receive chemotherapy.The final dose chemotherapy complete 8 month randomization patient receive prior adjuvant and/or neoadjuvant chemotherapy . 5 . Pregnant lactating . 6 . Patients previous concomitant invasive malignancy eligible . The exception patient follow ( follow ) malignancy ( previous concomitant ) eligible adequately treat : basal squamous cell carcinoma skin situ nonbreast carcinoma without invasion contra ipsilateral situ breast carcinoma nonbreast invasive malignancy diagnose least 5 year ago without recurrence : stage I papillary thyroid cancer stage Ia carcinoma cervix stage Ia b endometrioid endometrial cancer borderline stage I ovarian cancer 7 . Patients receive endocrine therapy ( include neoadjuvant adjuvant ) 8 month breast cancer diagnosis . 8 . Patients take tamoxifen selective estrogen receptor modulator ( SERM , e.g . Raloxifene ) hormone replacement therapy ( HRT ) within one year prior breast cancer diagnosis . 9 . Patients bilateral oophorectomy ovarian irradiation prior breast cancer diagnosis . 10 . With severe hepatic dysfunction , ChildPugh C. 11 . With severe cardiac dysfunction , New York Heart Association ( NYHA ) grade III worse . 12 . Known severe hypersensitivity drug study . 13 . Participants experimental drug clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>adjuvant endocrine therapy</keyword>
	<keyword>safety</keyword>
	<keyword>Exemestane</keyword>
	<keyword>ovarian function suppression</keyword>
	<keyword>anastrozole</keyword>
</DOC>